AGAZISIRAN
UNII RHG8LAD9CP

Substance Identification & Data

This profile provides standardized clinical and technical data for Agazisiran, uniquely identified by the FDA Unique Ingredient Identifier (UNII) RHG8LAD9CP.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2985646-78-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

RHG8LAD9CP

CAS Registry Number

2985646-78-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

AGAZISIRAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C215273

National Cancer Institute reference terminology for clinical and research data.

INN ID

13364

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

OP-88

Identifier assigned by the United States Adopted Names Council.

Substance Type

Agazisiran

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Agazisiran. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Agazisiran

Common Names & Synonyms

([3′-O-[2-[[[1-[17-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-3,6,9,12,15-pentaoxaheptadec-1-yl]-1H-1,2,3-triazol-4-yl]methyl]amino]-2-oxoethyl]-2′-O-[2-[bis[[1-[17-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-3,6,9,12,15-pentaoxaheptadec-1-yl]-1H-1,2,3-triazol-4-yl]methyl]amino]-2-oxoethyl]]U-(5′→5′)-spGm-sp-Gm-Am-Am-Gm-Gm-Am-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-Gm-Am-Um-GmUm-Cm-Um-sp-Am-(3′→3′)-sp-[1′-de(6-amino-9H-purin-9-yl)]A), complex with RNA (Um-sp-(2′-deoxy-2′-fluoro)A-sp-Gm-(2′-deoxy-2′-fluoro)A-Cm-(2′-deoxy-2′-fluoro)AUm-(2′-deoxy-2′-fluoro)C-Cm-(2′-deoxy-2′-fluoro)A-Gm-(2′-deoxy-2′-fluoro)A-Um-(2′-deoxy-2′-fluoro)A-Am-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)C-Um-(2′-deoxy-2′-fluoro)U-sp-Cm-sp-Cm) (1:1)

AGAZISIRAN [USAN]

O-[(2R,3S)-2-(hydroxymethyl)oxolan-3-yl] hydrogen all-P-ambo-3'-O-(2-{[(1-{17-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-3,6,9,12,15-pentaoxaheptadecan-1-yl}-1H-1,2,3-triazol-4-yl)methyl]amino}-2-oxoethyl)-2'-O-(2-{bis[(1-{17-[(2-acetamido2-deoxy-β-D-galactopyranosyl)oxy]-3,6,9,12,15-pentaoxaheptadecan-1-yl}-1H-1,2,3-triazol-4-yl)methyl]amino}-2-oxoethyl)-P-thiouridylyl-(5'→5')-2'-O-methyl-Pthioguanylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-Omethyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thio-3'-adenylate duplex with all-P-ambo-2'-O-methyl-P-thiocytidylyl-(5'→3')-2'-O-methyl-P-thiocytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-Omethyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methyl-P-thioguanylyl-(5'→3')-2'-deoxy-2'-fluoro-P-thioadenylyl-(5'→3')-2'-O-methyluridine

RNA, ([3′-O-[2-[[[1-[17-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-3,6,9,12,15-pentaoxaheptadec-1-yl]-1H-1,2,3-triazol-4-yl]methyl]amino]-2-oxoethyl]-2′-O-[2-[bis[[1-[17-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-3,6,9,12,15-pentaoxaheptadec-1-yl]-1H-1,2,3-triazol-4-yl]methyl]amino]-2-oxoethyl]]U-(5′→5′)-sp-Gm-sp-Gm-Am-Am-Gm-Gm-Am-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-Gm-Am-Um-Gm-Um-Cm-Um-sp-Am-(3′→3′)-sp-[1′-de(6-amino-9H-purin-9-yl)]A), complex with RNA (Um-sp-(2′-deoxy-2′-fluoro)A-sp-Gm-(2′-deoxy-2′-fluoro)A-Cm-(2′-deoxy-2′-fluoro)A-Um-(2′-deoxy-2′-fluoro)C-Cm-(2′-deoxy-2′-fluoro)A-Gm-(2′-deoxy-2′-fluoro)A-Um-(2′-deoxy-2′-fluoro)A-Am-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)C-Um-(2′-deoxy-2′-fluoro)U-sp-Cm-sp-Cm) (1:1)

agazisiran [INN]